New York State approves SQI Diagnostics’ ACCURATE COVID-19 antibody assay
New York State approves SQI Diagnostics’ ACCURATE COVID-19 antibody assay

New York State approves SQI Diagnostics’ ACCURATE COVID-19 antibody assay

Conditional approval makes a quick, accurate test for the presence of antibodies against
SARS-CoV-2 available in USA –

TORONTO, March 3, 2022 / PRNewswire / – SQI Diagnostics Inc. (“SQI” or “Company”) (TSXV: SQD) (OTCQB: SQIDF), leaders in the science of lung health, announced today the state of New York The Department of Health (NYSDOH) has granted conditional approval to its diagnostic test partner, KSL Diagnostics, Inc. Buffalo NYfor the EXACT COVID-19 antibody test.

“THE EXACT COVID-19 antibody test is the next generation of tools in the fight against COVID-19. It provides peace of mind because it can detect an immune response in both vaccinated and previously COVID-19 infected people. It also has the potential to provide the health system key insights and data in the relationship between antibody levels and groundbreaking infections and reinfections, “says Andrew Morris, CEO of SQI Diagnostics. “We’re bringing these tests to market now because we’m determined to do our part to end the pandemic.”

NYSDOH, under the Clinical Laboratory Evaluation Program, evaluates and authorizes laboratory-developed tests for use in the state of New York certified clinical laboratories that are subject to requirements equivalent to or more stringent than the 1988 Clinical Laboratory Improvement Amendments (CLIA). KSL is proud to partner with SQI to deliver this test and is licensed to test samples from anywhere in The United States” say Kevin LawsonPresident and CEO of KSL.

Access to the EXACT COVID-19 Antibody Test will now be available to physicians and their patients in The United States through AZOVA Inc, a telemedicine testing company that makes healthcare accessible and affordable for Americans through innovative solutions.

EXACT COVID-19 Antibody Test is an advanced COVID-19 antibody test that provides semiquantitative measurements of six different antibodies produced by the immune system in response to exposure to SARS CoV-2 virus or to COVID-19 vaccination. The small-volume blood sample can be taken at home or in the office with a finger stick. A positive test result may indicate the presence of antibodies derived from a previous COVID-19 infection or COVID-19 vaccination.

“The EXACT COVID-19 antibody test is an important part of SQI’s growing ability to offer unmatched clinical insight through varied and improved COVID-19 testing,” said Morris. “We are currently selling Health Canada approved test kits for SARS-CoV-2 RT-PCR molecular testing and point of care antigen testing products that enable rapid serial testing of asymptomatic populations. We have also submitted an application to Health Canada – for review under for Temporary Order — SQI’s RALI-Dx IL-6 test, a hospital-based respiratory triage test for COVID-19 positive patients. “

About SQI Diagnostics
SQI Diagnostics is a leader in the science of lung health. We develop and manufacture respiratory health and precision medical tests that run on SQI’s fully automated systems. Our tests simplify and improve COVID19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. We are driven by creating and marketing life-saving testing technologies that help more people in multiple places to live a longer and healthier life. For more information, please visit www.sqidiagnostics.com.

About AZOVA
AZOVA is a globally connected digital healthcare system that provides telehealth and digital healthcare services through globally connected providers, pharmacies and laboratory networks. AZOVA provides innovative COVID testing and vaccination solutions to employers, schools, government entities, airlines, the travel industry and consumers. AZOVA has created the world’s first truly connected global laboratory network to enable travelers to access COVID testing anywhere in the world. Visit azova.com for more information.

About KSL Diagnostics
KSL (www.ksldx.com) works the state of New York Department of Health / CLIA certified clinical laboratories licensed throughout the United States, including Beutner Laboratories and Robert Guthrie Laboratory. The fast-growing menu integrates standard care tests and new assays, developed at KSL and through partnerships with innovative diagnostic companies. KSL delivers superior compliance and industry-leading service standards.

Contact:
Morlan Reddock
Chief Accountant
437-235-6563
[email protected]

FUTURE INFORMATION

This news release contains certain forward-looking statements, including, without limitation, statements containing the words “will”, “may”, “expect”, “intend”, “anticipate” and other similar terms that constitute “forward-looking information” in the sense of applicable securities legislation. Forward-looking statements reflect the company’s current expectations and assumptions and are subject to a number of risks and uncertainties that may cause actual results to differ materially from those expected. The forward-looking statements in this news release include without limitation statements regarding the private placement, the repayment of the promissory note and the use of the proceeds of the private placement. These forward-looking statements are fully qualified by the inherent risks and uncertainties surrounding future expectations. Important factors that may cause actual results to differ materially from expectations include, but are not limited to, risks related to failure to obtain necessary regulators and stock market approvals for the Private Emission, general economic and market factors, competition, development and commercialization. of the Company’s diagnostic tests, the effect of the global pandemic and consequent economic disruption, and the factors described in the Company’s ongoing reports to the securities regulators available at www.sedar.com.

Although the forward-looking statements contained herein are based on what we consider to be reasonable assumptions based on information currently available to us, no assurance can be given that actual events, results or results will be consistent with these forward-looking statements, and our assumptions may prove to be incorrect. Readers are warned not to rely unnecessarily on these forward-looking statements. The Company assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This news release does not constitute an offer to sell or an invitation to sell any of the securities in The United States. The securities have not been and will not be registered under the US Securities Act or any government securities law and may not be offered or sold within The United States or to U.S. individuals, unless they are registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.

Neither the TSX Venture Exchange nor its regulatory service provider (as this term is defined in TSX Venture Exchange’s policies) assumes responsibility for the adequacy or accuracy of this release.

SOURCE SQI Diagnostics Inc.

Leave a Reply

Your email address will not be published.